Profund Advisors LLC Trims Holdings in Amgen Inc. $AMGN

Profund Advisors LLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,137 shares of the medical research company’s stock after selling 2,008 shares during the period. Amgen accounts for about 0.5% of Profund Advisors LLC’s holdings, making the stock its 29th largest holding. Profund Advisors LLC’s holdings in Amgen were worth $15,842,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Legacy Investment Solutions LLC bought a new stake in shares of Amgen during the 2nd quarter valued at about $27,000. Evelyn Partners Investment Management LLP purchased a new stake in Amgen in the second quarter worth about $32,000. Howard Hughes Medical Institute bought a new stake in Amgen during the 2nd quarter valued at approximately $32,000. Quaker Wealth Management LLC grew its holdings in shares of Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after acquiring an additional 240 shares during the period. Finally, Cloud Capital Management LLC purchased a new position in shares of Amgen during the 3rd quarter worth approximately $34,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $384.20 on Monday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm has a market cap of $206.88 billion, a price-to-earnings ratio of 27.00, a price-to-earnings-growth ratio of 3.96 and a beta of 0.46. The business has a 50-day simple moving average of $334.45 and a two-hundred day simple moving average of $311.51. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $385.12.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter last year, the firm posted $5.31 EPS. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 66.90%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Guggenheim raised their target price on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft raised their price objective on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday. Morgan Stanley boosted their target price on shares of Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. Argus increased their price target on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Erste Group Bank raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $351.65.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.